Search bioRxiv⌕ Search

Biology subjects

Rajurkar, P.

Publications and source records attributed to Rajurkar, P..

2 recordsLinked to original sources

Multimodal Sensitivity Enhancement of Binding-based Diagnostic Assays Using Functional Hydrogels

Immunoassays are critical for clinical diagnostics, yet their performance is restricted by the physical constraints of flat surfaces used to immobilize capture molecules which limit loading capacity and induce protein denaturation. Hydrogels provide immense volumetric molecular loading capacity but translating them across diverse assay formats and readout modalities without compromising analyte permeability remains challenging. Here, we present a universal strategy for hydrogel integration into immunoassay platforms for enhanced optical and electronic biosensing. Utilizing bio-orthogonal photo-click chemistry, we developed a modular and tuneable poly(ethylene glycol) (PEG) matrix that achieves a 6,000-fold increase in molecular loading and a large mesh size for analyte diffusion. This 3D architecture demonstrates broad multimodal utility with easy integration into a range of binding-based assays enabling higher sensitivity, repeatability and multiplexability. It achieves high sensitivity enhancement for fluorescence detection in microarrays (38-fold) and microtiter plates (25-fold) and enables multiplexed readout in single wells, including from clinical serum samples. In silver metallization-based assays it boosts densitometric optical detection sensitivity (18-fold) and enables inexpensive electronic detection. In lateral flow assays, it generates 20-fold signal enhancement while enabling multiplexability and higher repeatability. By standardizing high-capacity volumetric biosensing, this scalable, plug-and-play technology empowers next generation highly sensitive, field-deployable point-of-care diagnostics.

bioengineering↗

Dissolution-Controlled Nanocrystalline Rifapentine Formulation for Tuberculosis Treatment

Current tuberculosis (TB) treatment suffers from drawbacks such as long regimens, high pill burden and side effects leading to non-adherence and poor treatment outcomes. Dissolution-controlled drug depot formulation with high drug loading is a clinically successful drug delivery strategy. Such depots reduce the dosing frequency for treatments requiring daily administration, thereby improving treatment adherence and compliance. However, dissolution-controlled depots for first-line TB drugs have not been demonstrated due to their high solubility and high dose requirements. In this study, we overcame this challenge by developing injectable, extended-release, dissolution-controlled depots of nanocrystalline rifapentine (NCRPT), microcrystalline rifapentine (MCRPT) and amorphous rifapentine microparticles (ARPT) with more than 75% loading. Crystalline formulations resulted in much slower depot dissolution compared to amorphous formulations. A single intramuscular (IM) injection of NCRPT in mice resulted in therapeutic serum concentrations for over a week. We then demonstrated the efficacy of NCRPT in both pre-exposure prophylaxis and therapeutic models of mice TB. NCRPT administered at 60 mg/kg once every two weeks demonstrated excellent efficacy in a mouse model of TB infection. In each case, a [~] 4-log-fold reduction in lung bacterial load compared to untreated mice was observed. These results open new avenues for developing LAI formulations of TB drugs and could improve patient compliance and TB management.

bioengineering↗